Episode 39: R-CHOP versus DA-EPOCH-R for Double-Hit Lymphoma

Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), and Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, join the show for a long-awaited debate: treating double-hit lymphoma with R-CHOP vs dose-adjusted (DA)-EPOCH-R. The conversation gets testy when the trio describe double-hit lymphoma in terms of histology and phenotype, the limitations of retrospective analyses when it comes to establishing a standard of care for this type of lymphoma, an intense breakdown of the CALGB 50303 study as it relates to the treatment argument and toxicity profiles, and so much more.